W W,
They made a presentation at a technical conference on Saturday in which the trial results were presented, then they held an investors conference early this morning. You have to live with conference presentations when they're scheduled, but the announcement on Sunday should support a good week beginning on Monday. I suspect it's nearly as good as an announcement on Monday before the bell.
Frankly I'll be happy with whenever TLD and Journal are out, while news early in the week is generally best it just can't always be controlled. The company does have a choice when to issue TLD, the only question is whether they are willing to have it out days before the Journal, or if they want it simultaneously with the Journal, or perhaps even an announcement that's far more than a typical TLD statement that's made summarizing what's presented in the Journal. I don't believe that there are laws regarding what's in a TLD statement, but normally it's issued before any technical presentation. I don't know that if they waited for the presentation that they couldn't get away with that, who would be punishing them.
I'm still of the belief that Clinical Trials should be updated, but if it's essentially a European publication, perhaps they'll just rely on the goals established in Europe and the publishers will be satisfied with that. Annals is clearly recognized worldwide, but centered in Europe as I understand it, they may be happy publishing without the update of the U.S. Clinical Trials.
Frankly, I can't see why our Clinical Trials shouldn't be upgraded, but I don't know if they could update goals without also summarizing trial results, and that's not something they want to do until the Journal is out. If they could change the trial goals, I believe they'll read identical to those in Europe, but the trial has concluded, they have the results, the regulators may insist on a complete revision, not just the goals being changed.
Gary
News 
Market Data 
Discover 
